Dose optimization of piperacillin/tazobactam, cefepime, and ceftazidime for carbapenem-resistant Pseudomonas aeruginosa isolates in Turkiye

被引:0
|
作者
Buyukyanbolu, Ecem [1 ,2 ]
Gill, Christian M. [2 ]
Genc, Leyla [1 ]
Karakus, Mehmet [3 ]
Comert, Fusun [4 ]
Otlu, Baris [5 ]
Aktas, Elif [1 ]
Nicolau, David P. [2 ]
机构
[1] Univ Hlth Sci, Hamidiye Etfal Training & Res Hosp, Dept Med Microbiol, Istanbul, Turkiye
[2] Hartford Hosp, Ctr Antiinfect Res & Dev, 80 Seymour St, Hartford, CT 06102 USA
[3] Univ Hlth Sci, Dept Med Microbiol, Istanbul, Turkiye
[4] Bulent Ecevit Univ, Fac Med, Dept Med Microbiol, Zonguldak, Turkiye
[5] Inonu Univ, Fac Med, Dept Med Microbiol, Malatya, Turkiye
关键词
P; aeruginosa; Dose optimization; Cephalosporin; PK/PD; Carbapenem resistance; IN-VIVO EFFICACY; DOSING INTERVALS; THIGH-INFECTION; BETA-LACTAM; INFUSION; PHARMACODYNAMICS; PNEUMONITIS; MEROPENEM; IMIPENEM; OUTCOMES;
D O I
10.1007/s10096-024-04990-w
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction Although CRPA may test susceptible to other beta-lactams such as ceftazidime (CAZ), cefepime (FEP), and piperacillin/tazobactam (TZP), reduced potency has been observed. We assessed the adequacy of EUCAST Susceptible (S) or Susceptible Increased Exposure (SIE)/(I) doses for CAZ, FEP, and TZP against CRPA clinical isolates. Methods CRPA isolates were collected from patients at three Turkish hospitals. CAZ, FEP, and TZP MICs were determined using broth microdilution. Monte Carlo simulations were performed to determine the probability of target attainment (PTA) for a free time above the MIC (fT > MIC) targets for various doses of each agent against isolates defined as susceptible. fT > MIC targets were 70% for CAZ or FEP and 50% for TZP. Cumulative fraction of response (CFR) was calculated. Optimal PTA and CFR was 90% target achievement. Results The percentages of isolates SIE/I to CAZ, FEP, and TZP were 49,8%, 47%, and 31,8% respectively. Reduced potency was noted with 54,1% of CAZ-S isolates having MICs of 4 or 8 mg/L. Of the FEP and TZP-S isolates, MICs at the breakpoint (8 and 16 mg/L, respectively) were the mode with 45,2 and 53,9% of isolates for each, respectively. At an MIC of 8 mg/L for CAZ, the EUCAST standard dose was insufficient (CFR of 85%). 3 h infusions of EUCAST SIE doses were required for 90% PTA at MIC of 8 mg/L and an optimized CFR of 100%. For FEP, the SIE dose of 2 g q8h 0.5 h infusion of was effective (CFR 96%), utilization of an extended 3 h infusion further optimized the PTA at 8 mg/L (CFR 99%). For TZP, the standard dose of 4.5 q6h administered as a 0.5 h infusion was inadequate (CFR 86%). A standard TZP dose with an extended infusion (4.5 g q8h over 4 h) and the SIE dose 4.5 g q6h 3 h infusion resulted in CFRs > 95%. Conclusion These data support the EUCAST SIE breakpoints for FEP and TZP. To optimize PTA at the SIE breakpoint for CAZ, prolonged infusion is required.
引用
收藏
页码:159 / 165
页数:7
相关论文
共 50 条
  • [31] Evaluation of In Vitro Activity of Ceftolozane/Tazobactam and Ceftazidime/Avibactam Against Carbapenem-Resistant Pseudomonas aeruginosa Strains and Mechanisms of Carbapenem Resistance: Data from Tertiary Care Hospital
    Hazirolan, Gulsen
    Ozkul, Ceren
    JUNDISHAPUR JOURNAL OF MICROBIOLOGY, 2023, 16 (03)
  • [32] BIChromET: A Chromogenic Culture Medium for Detection of Piperacillin/Tazobactam and Cefepime Resistance in Pseudomonas aeruginosa
    de la Rosa, Jose Manuel Ortiz
    Rodriguez-Villodres, Angel
    Martin-Gutierrez, Guillermo
    Mairal, Carmen Cintora
    Escobar, Jose Luis Garcia
    Galvez-Benitez, Lydia
    Cisneros, Jose Miguel
    Lepe, Jose Antonio
    ANTIBIOTICS-BASEL, 2023, 12 (11):
  • [33] Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa
    Burgess, DS
    Nathisuwan, S
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 44 (01) : 35 - 41
  • [34] Bulgecin A as a β-lactam enhancer for carbapenem-resistant Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumannii clinical isolates containing various resistance mechanisms
    Skalweit, Marion J.
    Li, Mei
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 3013 - 3020
  • [35] Mutational inactivation of OprD in carbapenem-resistant Pseudomonas aeruginosa isolates from Korean hospitals
    Kim, Chi Hyun
    Kang, Hee Young
    Kim, Bo Ra
    Jeon, Hyejin
    Lee, Yoo Chul
    Lee, Sang Hwa
    Lee, Je Chul
    JOURNAL OF MICROBIOLOGY, 2016, 54 (01) : 44 - 49
  • [36] Mutational inactivation of OprD in carbapenem-resistant Pseudomonas aeruginosa isolates from Korean hospitals
    Chi Hyun Kim
    Hee Young Kang
    Bo Ra Kim
    Hyejin Jeon
    Yoo Chul Lee
    Sang Hwa Lee
    Je Chul Lee
    Journal of Microbiology, 2016, 54 : 44 - 49
  • [37] Synergistic effects of fosfomycin and carbapenems against carbapenem-resistant Pseudomonas aeruginosa clinical isolates
    Kunakonvichaya, Benjaporn
    Thirapanmethee, Krit
    Khuntayaporn, Piyatip
    Montakantikul, Preecha
    Chomnawang, Mullika Traidej
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2015, 45 (05) : 556 - 557
  • [38] Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa
    Lasarte-Monterrubio, Cristina
    Arturo Fraile-Ribot, Pablo
    Carlos Vazquez-Ucha, Juan
    Cabot, Gabriel
    Guijarro-Sanchez, Paula
    Alonso-Garcia, Isaac
    Rumbo-Feal, Soraya
    Galan-Sanchez, Fatima
    Beceiro, Alejandro
    Arca-Suarez, Jorge
    Oliver, Antonio
    Bou, German
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (10) : 2809 - 2815
  • [39] Evaluation of three commercial methods of susceptibility testing for ceftolozane/tazobactam against carbapenem-resistant Pseudomonas aeruginosa
    Lopez-Cerero, Lorena
    Ballesta, Sofia
    Lopez, Cristina Elias
    Sanchez-Yebra, Waldo
    Rojo-Martin, Maria Dolores
    Pascual, Alvaro
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2023, 41 (10): : 621 - 624
  • [40] Ceftazidime-Avibactam Susceptibility Patterns of Carbapenem-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa Clinical Strains in a Tertiary-Care Educational Hospital in Turkiye
    Noyan, Ayse
    Sipahi, Oguz Resat
    Cilli, Feriha
    Aydemir, Sohret
    FLORA INFEKSIYON HASTALIKLARI VE KLINIK MIKROBIYOLOJI DERGISI, 2024, 29 (01): : 161 - 163